Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation

The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antiviral...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Thiago Moreno L. Souza, Vagner D. Pinho, Cristina F. Setim, Carolina Q. Sacramento, Rodrigo Marcon, Natalia Fintelman-Rodrigues, Otavio A. Chaves, Melina Heller, Jairo R. Temerozo, André C. Ferreira, Mayara Mattos, Patrícia B. Momo, Suelen S. G. Dias, João S. M. Gesto, Filipe Pereira-Dutra, João P. B. Viola, Celso Martins Queiroz-Junior, Lays Cordeiro Guimarães, Ian Meira Chaves, Pedro Pires Goulart Guimarães, Vivian Vasconcelos Costa, Mauro Martins Teixeira, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Anderson R. Aguillón, Jarbas Siqueira-Junior, Sergio Macedo-Junior, Edineia L. Andrade, Guilherme P. Fadanni, Sara E. L. Tolouei, Francine B. Potrich, Adara A. Santos, Naiani F. Marques, João B. Calixto, Jaime A. Rabi
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-01-01
Online Access:	https://doi.org/10.1038/s41467-023-35928-z